407: The mysterious case of Eli Lilly's obesity drug
Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good investment?
We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. We bring on our colleague Lizzy Lawrence to discuss her scoop that Lilly and the Food and Drug Administration have allowed one person to receive the pharma company's obesity candidate, retatrutide, through the FDA’s “compassionate use” program.
We also discuss the resurgence of M&A, Lilly's interest in a hair loss drug, and then the FDA's reversal on rare disease drugs.
We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. We bring on our colleague Lizzy Lawrence to discuss her scoop that Lilly and the Food and Drug Administration have allowed one person to receive the pharma company's obesity candidate, retatrutide, through the FDA’s “compassionate use” program.
We also discuss the resurgence of M&A, Lilly's interest in a hair loss drug, and then the FDA's reversal on rare disease drugs.
Loading content...
Read the full transcript
Matterfact has every podcast on Apple Podcasts and Spotify: 700K+ channels, 120M+ episodes.
The candid version is on a podcast,
not the earnings call.
Matterfact turns the conversations your coverage is already having into a searchable, citable record — across every episode, not just this one.